Incidence of induced abortion among commercially insured pregnant patients with cancer.

Swartz, Jonas J; Huang, Yongmei; Wu, Jenny; Moss, Haley; Hershman, Dawn L; Wright, Jason D

Swartz, Jonas J; Huang, Yongmei; Wu, Jenny; Moss, Haley; Hershman, Dawn L; Wright, Jason D.

Afiliación

Swartz JJ; Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA. Electronic address: Jonas.swartz@duke.edu.
Huang Y; Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Wu J; Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.
Moss H; Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.
Hershman DL; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Wright JD; Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Contraception ; : 110511, 2024 Jun 04.

Article en En | MEDLINE | ID: mdl-38844202

ABSTRACT

ABSTRACT

OBJECTIVES:

This study aimed to characterize pregnancy outcomes and the incidence of induced abortion among pregnant people with a diagnosis of malignancy. STUDY

DESIGN:

We conducted a retrospective cohort study among privately insured people aged 12 to 55 years from the fourth quarter of 2015-2020 using US claims data from Merative MarketScan Research Databases. We included pregnancies from seven states with favorable policies for private insurance coverage of abortion.

RESULTS:

There were 1471 of 183,685 (0.8%) pregnancies with a cancer diagnosis. Among those receiving anticancer therapy, 21.6% (95% CI 14.4-30.4%) underwent induced abortion compared with 10.9% (95% CI 10.8-11.1%) of pregnant patients without a cancer diagnosis.